Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Although the development of effective, oral medications for chronic hepatitis C virus infection (HCV) is a scientific triumph, the high price of the newest, directly acting antiviral agents, simeprevir and sofosbuvir, has sparked a much-needed debate about the fair pricing of pharmaceuticals. In the United States, the costs for 12 weeks of therapy, for the drugs alone, can range from $66 360 for simeprevir to $84 000 for sofosbuvir, or $1000 per tablet of the latter medication.1
Steinbrook R, Redberg RF. The High Price of the New Hepatitis C Virus Drugs. JAMA Intern Med. 2014;174(7):1172. doi:10.1001/jamainternmed.2014.2135